JP2023536974A5 - - Google Patents
Info
- Publication number
- JP2023536974A5 JP2023536974A5 JP2023507767A JP2023507767A JP2023536974A5 JP 2023536974 A5 JP2023536974 A5 JP 2023536974A5 JP 2023507767 A JP2023507767 A JP 2023507767A JP 2023507767 A JP2023507767 A JP 2023507767A JP 2023536974 A5 JP2023536974 A5 JP 2023536974A5
- Authority
- JP
- Japan
- Prior art keywords
- rnai oligonucleotide
- ome
- pharmaceutical composition
- sense strand
- galnac
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024034617A JP7805386B2 (ja) | 2020-08-05 | 2024-03-07 | Ｌｐａ発現を阻害するための組成物及び方法 |
| JP2026003542A JP2026077639A (ja) | 2020-08-05 | 2026-01-13 | Ｌｐａ発現を阻害するための組成物及び方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063061676P | 2020-08-05 | 2020-08-05 | |
| US63/061,676 | 2020-08-05 | ||
| US202063074779P | 2020-09-04 | 2020-09-04 | |
| US63/074,779 | 2020-09-04 | ||
| PCT/US2021/071109 WO2022032288A1 (en) | 2020-08-05 | 2021-08-05 | Compositions and methods for inhibiting lpa expression |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024034617A Division JP7805386B2 (ja) | 2020-08-05 | 2024-03-07 | Ｌｐａ発現を阻害するための組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023536974A JP2023536974A (ja) | 2023-08-30 |
| JP2023536974A5 true JP2023536974A5 (enExample) | 2023-11-16 |
| JP7476422B2 JP7476422B2 (ja) | 2024-04-30 |
Family
ID=77519885
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023507767A Active JP7476422B2 (ja) | 2020-08-05 | 2021-08-05 | Ｌｐａ発現を阻害するための組成物及び方法 |
| JP2024034617A Active JP7805386B2 (ja) | 2020-08-05 | 2024-03-07 | Ｌｐａ発現を阻害するための組成物及び方法 |
| JP2026003542A Pending JP2026077639A (ja) | 2020-08-05 | 2026-01-13 | Ｌｐａ発現を阻害するための組成物及び方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024034617A Active JP7805386B2 (ja) | 2020-08-05 | 2024-03-07 | Ｌｐａ発現を阻害するための組成物及び方法 |
| JP2026003542A Pending JP2026077639A (ja) | 2020-08-05 | 2026-01-13 | Ｌｐａ発現を阻害するための組成物及び方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US12435336B2 (enExample) |
| EP (1) | EP4192954A1 (enExample) |
| JP (3) | JP7476422B2 (enExample) |
| KR (2) | KR20250077604A (enExample) |
| CN (1) | CN116323943A (enExample) |
| AU (2) | AU2021320550B2 (enExample) |
| BR (1) | BR112023001957A2 (enExample) |
| CA (1) | CA3185348A1 (enExample) |
| IL (1) | IL300338A (enExample) |
| MX (1) | MX2023001538A (enExample) |
| TW (2) | TWI886314B (enExample) |
| WO (1) | WO2022032288A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250077604A (ko) | 2020-08-05 | 2025-05-30 | 다이서나 파마수이티컬, 인크. | Lpa 발현을 저해하기 위한 조성물 및 방법 |
| WO2023041079A1 (zh) * | 2021-09-18 | 2023-03-23 | 上海金中锘美生物医药科技有限公司 | Lpa抑制剂及其用途 |
| KR20240103025A9 (ko) | 2021-11-16 | 2025-12-10 | 상하이 아르고 바이오파마슈티칼 씨오., 엘티디. | 안지오텐시노겐(agt) 단백질의 발현을 저해하는 조성물 및 방법 |
| EP4450624A4 (en) * | 2021-12-16 | 2025-03-26 | Tuojie Biotech (Shanghai) Co., Ltd. | LPA-TARGETTING SIRNA AND CONJUGATE |
| CN114703184B (zh) * | 2022-03-11 | 2024-06-18 | 厦门甘宝利生物医药有限公司 | Lpa抑制剂及其用途 |
| JP2025512445A (ja) * | 2022-04-15 | 2025-04-17 | ディセルナ ファーマシューティカルズ インコーポレイテッド | Ｓｃａｐ活性を調節するための組成物及び方法 |
| WO2024035898A2 (en) * | 2022-08-11 | 2024-02-15 | Sirius Therapeutics, Inc. | Polynucleic acid molecules for inhibiting expression of lp(a), pharmaceutical compositions, and uses thereof |
| WO2024081954A2 (en) | 2022-10-14 | 2024-04-18 | Sanegene Bio Usa Inc. | Small interfering rna targeting c3 and uses thereof |
| CN115851723B (zh) * | 2022-10-24 | 2023-10-03 | 厦门甘宝利生物医药有限公司 | 一种抑制lpa基因表达的rna抑制剂及其应用 |
| JP7812495B2 (ja) | 2022-11-23 | 2026-02-09 | イーライ リリー アンド カンパニー | ４’－ホスフェート類似体ヌクレオチドホスホラミダイトを合成する方法 |
| EP4622982A1 (en) | 2022-11-23 | 2025-10-01 | Eli Lilly and Company | Methods of synthesizing a targeting ligand-conjugated nucleotide phosphoramidite |
| EP4638744A1 (en) | 2022-12-22 | 2025-10-29 | Eli Lilly and Company | Oligonucleotide fragments and methods of making rnai agents using the same |
| KR20250131826A (ko) | 2023-01-13 | 2025-09-03 | 일라이 릴리 앤드 캄파니 | 치료 올리고뉴클레오티드-함유 제약 조성물 및 그를 사용한 투여 요법 |
| WO2024197065A2 (en) * | 2023-03-20 | 2024-09-26 | Verve Therapeutics, Inc. | In vivo nickase-based editing of the lpa gene for treatment of cardiovascular disease |
| CN118685405A (zh) * | 2023-06-20 | 2024-09-24 | 施能康医药科技(苏州)有限公司 | 靶向脂蛋白a的核酸及其用途 |
| UY40897A (es) | 2023-09-21 | 2025-03-31 | Ionis Pharmaceuticals Inc | Compuestos y métodos para inhibir lpa |
| WO2025082058A1 (zh) * | 2023-10-16 | 2025-04-24 | 润佳(上海)医药技术有限公司 | 一种抑制LPA基因表达的dsRNA及其用途 |
| CN120344664A (zh) * | 2023-10-27 | 2025-07-18 | 北京安龙生物医药有限公司 | 靶向脂蛋白a的寡核苷酸及其用途 |
| CN120020252A (zh) * | 2023-11-17 | 2025-05-20 | 纳肽得(青岛)生物医药有限公司 | 抑制LPA表达的siRNA及其用途 |
| CN122514601A (zh) * | 2023-11-29 | 2026-08-04 | 美国圣因生物股份有限公司 | 靶向Lp(a)的小干扰RNA及其用途 |
| CN120098993A (zh) * | 2023-12-05 | 2025-06-06 | 广东东阳光药业股份有限公司 | 一种新型的双链siRNA、其缀合物及其用途 |
| TW202546233A (zh) * | 2024-02-05 | 2025-12-01 | 美商靖因藥業（上海）有限公司 | 用於抑制ｌｐ（ａ）或ａｐｏｃ３之表現的多核酸分子、醫藥組合物及其用途 |
| WO2026026890A1 (zh) * | 2024-07-31 | 2026-02-05 | 前沿生物药业(南京)股份有限公司 | 用于抑制LPA基因表达的siRNA及其修饰物与应用 |
| WO2026057051A1 (zh) * | 2024-09-14 | 2026-03-19 | 深圳信立泰药业股份有限公司 | 一种用于抑制细胞中LPA基因表达的RNAi剂、其制备方法及用途 |
| WO2026092650A1 (zh) * | 2024-11-01 | 2026-05-07 | 迈威(上海)生物科技股份有限公司 | 一种抑制LPA基因表达的RNAi制剂及其应用 |
| WO2026133253A1 (en) | 2024-12-20 | 2026-06-25 | Novartis Ag | Combinations of antisense agents, pharmaceutical compositions and methods of use |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6469158B1 (en) | 1992-05-14 | 2002-10-22 | Ribozyme Pharmaceuticals, Incorporated | Synthesis, deprotection, analysis and purification of RNA and ribozymes |
| US5804683A (en) | 1992-05-14 | 1998-09-08 | Ribozyme Pharmaceuticals, Inc. | Deprotection of RNA with alkylamine |
| US5977343A (en) | 1992-05-14 | 1999-11-02 | Ribozyme Pharmaceuticals, Inc. | Synthesis, deprotection, analysis and purification of RNA and ribozymes |
| EP1253199A1 (en) | 1993-09-02 | 2002-10-30 | Ribozyme Pharmaceuticals, Inc. | Abasic moieties containing enzymatic nucleic acids |
| US5889136A (en) | 1995-06-09 | 1999-03-30 | The Regents Of The University Of Colorado | Orthoester protecting groups in RNA synthesis |
| US5998203A (en) | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
| US6111086A (en) | 1998-02-27 | 2000-08-29 | Scaringe; Stephen A. | Orthoester protecting groups |
| KR20080023768A (ko) | 2000-03-30 | 2008-03-14 | 화이트헤드 인스티튜트 포 바이오메디칼 리서치 | Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체 |
| CN100523215C (zh) | 2000-12-01 | 2009-08-05 | 马普科技促进协会 | 介导rna干涉的小rna分子 |
| US20050159378A1 (en) | 2001-05-18 | 2005-07-21 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA) |
| WO2003040395A2 (en) | 2001-11-07 | 2003-05-15 | Applera Corporation | Universal nucleotides for nucleic acid analysis |
| US20070265220A1 (en) | 2004-03-15 | 2007-11-15 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
| WO2007030167A1 (en) | 2005-09-02 | 2007-03-15 | Nastech Pharmaceutical Company Inc. | Modification of double-stranded ribonucleic acid molecules |
| WO2010033225A2 (en) | 2008-09-22 | 2010-03-25 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for the specific inhibition of gene expression by dsrna possessing modifications |
| WO2010039543A2 (en) | 2008-09-23 | 2010-04-08 | Traversa Therapeutics, Inc. | Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference |
| KR20110110776A (ko) | 2008-12-18 | 2011-10-07 | 다이서나 파마수이티컬, 인크. | 유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법 |
| WO2010093788A2 (en) | 2009-02-11 | 2010-08-19 | Dicerna Pharmaceuticals, Inc. | Multiplex dicer substrate rna interference molecules having joining sequences |
| US8927513B2 (en) | 2009-07-07 | 2015-01-06 | Alnylam Pharmaceuticals, Inc. | 5′ phosphate mimics |
| US9725479B2 (en) | 2010-04-22 | 2017-08-08 | Ionis Pharmaceuticals, Inc. | 5′-end derivatives |
| AU2012328680A1 (en) | 2011-10-25 | 2014-05-01 | Ionis Pharmaceuticals, Inc. | Antisense modulation of GCCR expression |
| EP2928877B1 (en) | 2012-12-06 | 2020-01-22 | Merck Sharp & Dohme Corp. | Disulfide masked prodrug compositions and methods |
| CN107109405A (zh) | 2014-06-06 | 2017-08-29 | 索尔斯蒂斯生物有限公司 | 具有生物可逆性和非生物可逆性基团的多核苷酸构建体 |
| EP3865576A1 (en) | 2014-12-15 | 2021-08-18 | Dicerna Pharmaceuticals, Inc. | Ligand-modified double-stranded nucleic acids |
| JOP20160211B1 (ar) | 2015-10-01 | 2021-08-17 | Arrowhead Pharmaceuticals Inc | تراكيب وأساليب لتثبيط تعبير جيني للـ lpa |
| WO2018045317A1 (en) | 2016-09-02 | 2018-03-08 | Dicerna Pharmaceuticals, Inc. | 4'-phosphate analogs and oligonucleotides comprising the same |
| CN119120476A (zh) | 2017-11-13 | 2024-12-13 | 赛伦斯治疗有限责任公司 | 用于抑制细胞中lpa的表达的核酸 |
| AR113490A1 (es) * | 2017-12-12 | 2020-05-06 | Amgen Inc | CONSTRUCCIONES DE ARNi PARA INHIBIR LA EXPRESIÓN DE PNPLA3 Y MÉTODOS DE USO DE LAS MISMAS |
| JP7827623B2 (ja) * | 2019-12-09 | 2026-03-10 | アムジエン・インコーポレーテツド | ＬＰＡ発現を阻害するためのＲＮＡｉコンストラクト及び方法 |
| KR20250077604A (ko) | 2020-08-05 | 2025-05-30 | 다이서나 파마수이티컬, 인크. | Lpa 발현을 저해하기 위한 조성물 및 방법 |
-
2021
- 2021-08-05 KR KR1020257016689A patent/KR20250077604A/ko active Pending
- 2021-08-05 TW TW110128888A patent/TWI886314B/zh active
- 2021-08-05 EP EP21762318.0A patent/EP4192954A1/en active Pending
- 2021-08-05 WO PCT/US2021/071109 patent/WO2022032288A1/en not_active Ceased
- 2021-08-05 TW TW114118397A patent/TW202535432A/zh unknown
- 2021-08-05 US US18/040,302 patent/US12435336B2/en active Active
- 2021-08-05 BR BR112023001957A patent/BR112023001957A2/pt unknown
- 2021-08-05 JP JP2023507767A patent/JP7476422B2/ja active Active
- 2021-08-05 CA CA3185348A patent/CA3185348A1/en active Pending
- 2021-08-05 CN CN202180058046.7A patent/CN116323943A/zh active Pending
- 2021-08-05 IL IL300338A patent/IL300338A/en unknown
- 2021-08-05 MX MX2023001538A patent/MX2023001538A/es unknown
- 2021-08-05 AU AU2021320550A patent/AU2021320550B2/en active Active
- 2021-08-05 KR KR1020237006019A patent/KR102812602B1/ko active Active
-
2024
- 2024-03-07 JP JP2024034617A patent/JP7805386B2/ja active Active
- 2024-08-16 US US18/807,591 patent/US12252691B2/en active Active
-
2025
- 2025-08-04 US US19/290,213 patent/US20260071219A1/en active Pending
- 2025-10-17 AU AU2025252633A patent/AU2025252633A1/en active Pending
-
2026
- 2026-01-13 JP JP2026003542A patent/JP2026077639A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024081668A5 (enExample) | ||
| JP2023518409A5 (enExample) | ||
| JP7442574B2 (ja) | Ｌｐａの遺伝子発現の阻害のための組成物及び方法 | |
| JP2021518125A5 (enExample) | ||
| CN113164509B (zh) | 用于抑制17β-HSD 13型(HSD17B13)表达的RNAi试剂、其组合物和使用方法 | |
| JP7476422B2 (ja) | Ｌｐａ発現を阻害するための組成物及び方法 | |
| TWI826365B (zh) | α-1抗胰蛋白酶 (AAT) RNAi 藥劑、包含AAT RNAi 藥劑之組合物及使用方法 | |
| TWI881004B (zh) | 用於治療ｈｂｖ之靶向ｈｂｖ的治療性寡核苷酸及ｔｌｒ７促效劑之醫藥組合 | |
| TW201922264A (zh) | 用於抑制類血管生成素蛋白-3(ANGPTL3)表現的RNAi藥劑及組合物及使用方法 | |
| JP2022553348A5 (enExample) | ||
| JP2022501040A5 (enExample) | ||
| JP2024514880A5 (enExample) | ||
| JP2024535888A5 (enExample) | ||
| JP2023530461A5 (enExample) | ||
| JP2022526419A (ja) | 中枢神経系における遺伝子発現を阻害するための組成物及び方法 | |
| JP2020529197A5 (enExample) | ||
| JP2023538284A5 (enExample) | ||
| TW202113079A (zh) | 經修飾之間隙子寡核苷酸及其使用方法 | |
| JP2018529732A5 (enExample) | ||
| JP2024516356A5 (enExample) | ||
| JP2018525030A5 (enExample) | ||
| JP2023519246A5 (enExample) | ||
| JP2022520986A5 (enExample) | ||
| JP2023529903A5 (enExample) | ||
| KR20240101580A (ko) | Hbv 치료를 위한 약학 조합물 |